CTLA4 and neoplasm: Checkpoint inhibitors, such as PD-1 and CTLA-4 blockers, function by preventing interactions between PD-1 and PD-L1 on tumor cells or between CTLA-4 and CD80+ on antigen-presenting cells [2, 6–9].